CLINICAL APPLICATIONS OF DELTA OPIATE RECEPTOR LIGANDS

DESCRIPTION: (adapted from applicant's abstract) The objective of this proposal is to advance a delta agonist opioid compound, DP13338W95, into clinical trials as a postoperative treatment for respiratory depression induced by mu-opioid analgesics. It has been shown that DP13338W95 is capable of attenuating respiratory depression produced by mu agonists; it is important to establish whether it can also antagonize other mu- specific effects such as dependence, drug seeking behavior, and emesis. The three aims of this Phase 1 application are to synthesize approximately 2 grams of the compound for further studies, to assess whether DP13338W95 has abuse potential, and to determine which of three clinically used analgesics can best be combined with DE13338W95 to produce adequate analgesia with minimal respiratory depression. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 242 --PROJECT NUMBER......1 R43 DA11350-01 INVESTIGATOR NAME/ADDRESS FY 97 BAIRD, JOHN IRG/INTRAMURAL UNIT..ZRG5 APPLIED BEHAVIORAL RESEARCH AWARD AMOUNT......... $97,663 HAMDEN, CT 06517 PERFORMING ORGANIZATION: APPLIED BEHAVIORAL RESEARCH TITLE HIV RISK REDUCTION QUESTIONNAIRE AND INTERVIEW ABSTRACT: Because reducing transmission of HIV infection among drug-abusing populations is a major focus of drug abuse treatment and research, reliable assessment and quantification of sexual and drug-use behaviors associated with HIV infection is critical. Generally, the existing instruments do not have sufficiently established psychometric properties and cover a limited number of issues, often excluding the relationship between sexual and drug-related behaviors. With a long-term commercial objective of developing an assessment instrument that is practical for use in a wide spectrum of clinical and research settings, the Investigator plans to develop a psychometrically sound self-administered questionnaire and interview to assess sexual and drug-related risk behaviors in substance abusing populations. His goal is to develop an instrument that is: (a) sensitive to detect change in risk of HIV infection (e.g., resulting from participation in a drug abuse treatment program); and (b) sensitive to gender and cultural differences. In Phase I, these researchers will screen the existing assessments of risk of HIV infection, review the relevant literature, construct a draft version of the questionnaire and interview, and perform pilot tests of both version and the draft. Information obtained in Phase I will be used in development of commercial versions of both versions of the instrument. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 243 --PROJECT NUMBER......1 R43 DA11352-01 INVESTIGATOR NAME/ADDRESS FY 97 SHOLOMSKAS, DIANE E IRG/INTRAMURAL UNIT..ZRG5 APPLIED BEHAVIORAL RESEARCH AWARD AMOUNT......... $99,018 2 WHITNEY AVENUE NEW HAVEN, CT 06510 PERFORMING ORGANIZATION: APPLIED BEHAVIORAL RESEARCH TITLE EVALUATING MANUAL-GUIDED TRAINING IN CLINICAL SETTINGS ABSTRACT: There is a critical need for effective methods of technology transfer, that is, conveying psychosocial treatments found to be effective in clinical trials of drug abusers to clinical practice. Cognitive-behavioral strategies have been found to be effective for the treatment of cocaine dependence, but barriers to implementation of this approach in traditional settings exist. With a long-term commercial objective of developing a Technology Transfer and Training Institute for promoting the effective use of empirically validated treatments for substance use disorders, we plan to conduct a pilot feasibility study to evaluate the effectiveness of a training protocol for Cognitive-Behavioral treatment on the ability of clinicians in non-research clinical settings to deliver this treatment competently and in accordance with manual guidelines, compared with clinicians who read the manual but receive no formal training. In Phase I, we will develop a clinicians' training package and conduct a pilot study to evaluate the impact of the training protocol on clinicians' delivery of CBT techniques. In Phase II we will modify and expand the training protocol and conduct a larger randomized trial to evaluate the impact of the modified training protocol on patient outcomes as well.